Qatar Investment Authority in BioXcel Therapeutics, Inc.
Completed. First disclosed December 18, 2024, in a Schedule 13G (source).
- Investor
- Qatar Investment Authority (Qatar)
- Target
- BioXcel Therapeutics, Inc. (EDGAR CIK 1720893)
- Target country
- United States
- Sector
- Health and Life Sciences (SIC 2834)
- First disclosed
- December 18, 2024, Schedule 13G
- Amount
- Not stated
- Stake at first disclosure
- 5.20%
- Latest stated stake
- 0.6% (March 30, 2026)
Source Filings and Releases
| Date | Document | Stated stake | Link |
|---|---|---|---|
| December 18, 2024 | Schedule 13G | 5.20% | View |
| March 30, 2026 | Schedule 13G/A | 0.6% | View |
Cite: Middle East Forum, “Qatar Investment Authority in BioXcel Therapeutics, Inc.,” Gulf Sovereign Holdings, accessed October 13, 2026, https://statemoney.meforum.org/deal/qia-bioxcel-therapeutics-inc-1720893/.
Gulf money also reaches U.S. universities and lobbyists: the Influence Tracker holds Section 117 gift and contract disclosures and FARA registrations, and the Campus Watch Map places that funding on specific campuses.